BACKGROUND All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
F. Lo‐Coco,G. Avvisati,M. Vignetti,C. Thiede,S. Orlando,S. Iacobelli,F. Ferrara,P. Fazi,L. Cicconi,E. di Bona,G. Specchia,S. Sica,M. Divona,A. Levis,W. Fiedler,E. Cerqui,M. Breccia,G. Fioritoni,H. Salih,M. Cazzola,L. Melillo,A. Carella,C. Brandts,E. Morra,M. von Lilienfeld-Toal,B. Hertenstein,M. Wattad,M. Lübbert,M. Hänel,N. Schmitz,H. Link,M. Kropp,A. Rambaldi,G. La Nasa,M. Luppi,F. Ciceri,O. Finizio,A. Venditti,F. Fabbiano,K. Döhner,M. Sauer,A. Ganser,S. Amadori,F. Mandelli,H. Döhner,G. Ehninger,R. Schlenk,U. Platzbecker
Published 2013 in New England Journal of Medicine
ABSTRACT
PUBLICATION RECORD
- Publication year
2013
- Venue
New England Journal of Medicine
- Publication date
2013-07-10
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
CONCEPTS
- acute promyelocytic leukemia
A subtype of acute myeloid leukemia targeted by the treatment regimens compared in this trial.
Aliases: APL
- atra plus arsenic trioxide
The investigational treatment arm combining all-trans retinoic acid with arsenic trioxide for induction and consolidation therapy.
Aliases: ATRA-arsenic trioxide, ATRA + arsenic trioxide, all-trans retinoic acid plus arsenic trioxide
- atra plus chemotherapy
The standard comparator arm using all-trans retinoic acid with idarubicin induction, chemotherapy-based consolidation, and maintenance therapy.
Aliases: ATRA-chemotherapy, ATRA + chemotherapy, all-trans retinoic acid plus chemotherapy
- complete remission
The absence of detectable active leukemia after induction therapy, used here as an early treatment outcome.
Aliases: CR
- event-free survival
The time from treatment to relapse, progression, death, or other predefined events, measured at 2 years in this trial.
Aliases: EFS
- hematologic toxicity
Blood-related treatment adverse effects assessed by comparing the safety profiles of the two regimens.
Aliases: blood toxicity
- hepatic toxicity
Liver-related adverse effects observed during treatment with the compared regimens.
Aliases: liver toxicity
- low-to-intermediate-risk apl
Patients with acute promyelocytic leukemia and a white-cell count of 10×10^9 per liter or less, which defined the trial population.
Aliases: low-to-intermediate risk APL, low-intermediate-risk APL
- overall survival
The time from treatment to death from any cause, used as a clinical efficacy endpoint in the trial.
Aliases: OS
REFERENCES
Showing 1-42 of 42 references · Page 1 of 1